Results from the three-arm HIV prevention trial VOICE – Vaginal and Oral Interventions to Control the Epidemic – were recently presented at the 20th Conference on Retroviruses and Opportunistic Infections. The data showed that none of three interventions tested—daily oral tenofovir, daily oral TDF/FTC (Truvada), and daily 1% vaginal tenofovir gel—provided additional protection against HIV in this study, likely because few of the women in the trial used the products as directed.
This global advocates’ webinar included a presentation of the data from VOICE co-principal investigator Jeanne Marrazzo followed by a moderated discussion, which included clarifying questions around the trial itself as well as discussion of the implications these results have for ongoing and planned HIV prevention research and implementation.